Patents Assigned to Flow Pharma, Inc.
  • Publication number: 20210292406
    Abstract: An injectable formulation, comprising: poly(lactic-co-glycolic (PLGA) microsphere encapsulating siltuximab, wherein microspheres are sized to release siltuximab over a period of hours, days and weeks, where the biocompatible polymer releases antibody at an absorption rate which is characterized by an absorption rate constant (Ka (h?1) in the range of (0.001 to 2.048)+/?20%, or +/?10%, or +/?5%. for use and treating human patients with infections. The invention includes treating patients with viral infections of SARS-Cov-2 using siltuximab.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 23, 2021
    Applicant: Flow Pharma, Inc.
    Inventors: Reid M. Rubsamen, Scott Burkholtz, Charles V. Herst, Tom Hodge, Lu Wang
  • Publication number: 20200276288
    Abstract: A method of making a personalized cancer vaccine is disclosed. The method includes predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and creating a particle containing the neoantigen with the stronger predicted binding affinity. The predicting step can be implemented using artificial intelligence, statistical modeling, or a combination thereof. Particles are created by encapsulating the neoantigen with the stronger predicted binding affinity for the HLA complex of the patient in a biocompatible material. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine.
    Type: Application
    Filed: March 2, 2020
    Publication date: September 3, 2020
    Applicant: FLOW PHARMA, INC.
    Inventors: REID M. RUBSAMEN, CHARLES V. HERST, LU WANG, SCOTT R. BURKHOLZ, RICHARD T. CARBACK, III, SERBAN I. CIOTOS
  • Publication number: 20200276289
    Abstract: A personalized cancer vaccine is disclosed. The vaccine is comprised of particles encapsulating neoantigens. The neoantigens are chosen by predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and using the neoantigen with the stronger predicted binding affinity. Such a predicting step includes artificial intelligence, statistical modeling, or a combination thereof. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine.
    Type: Application
    Filed: March 2, 2020
    Publication date: September 3, 2020
    Applicant: FLOW PHARMA, INC.
    Inventors: REID M. RUBSAMEN, CHARLES V. HERST, LU WANG, SCOTT R. BURKHOLZ, RICHARD T. CARBACK, III, SERBAN I. CIOTIOS
  • Publication number: 20190105387
    Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 11, 2019
    Applicant: FLOW PHARMA, INC.
    Inventors: REID M. RUBSAMEN, DAVID EARL HECKERMAN
  • Patent number: 10172936
    Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which may be a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: January 8, 2019
    Assignee: FLOW PHARMA, INC.
    Inventors: Reid M. Rubsamen, David Earl Heckerman
  • Publication number: 20160324956
    Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which may be a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 10, 2016
    Applicant: FLOW PHARMA, INC.
    Inventors: REID M. RUBSAMEN, DAVID EARL HECKERMAN
  • Patent number: 9408906
    Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: August 9, 2016
    Assignee: FLOW PHARMA, INC.
    Inventors: Reid M. Rubsamen, David Earl Heckerman
  • Publication number: 20150132398
    Abstract: A vaccine formulation as disclosed which is comprised of a pharmaceutically acceptable carrier in a plurality of particles with mannose on their surface. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence which corresponds to a sequence on a surface of a pathogen. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than a single particle from being presented to a single immune system cell.
    Type: Application
    Filed: January 21, 2015
    Publication date: May 14, 2015
    Applicant: FLOW PHARMA, INC.
    Inventors: CHARLES VINCENT TAYLOR HERST, REID M. RUBSAMEN
  • Publication number: 20130142878
    Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which may be a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.
    Type: Application
    Filed: November 30, 2012
    Publication date: June 6, 2013
    Applicant: FLOW PHARMA, INC.
    Inventor: FLOW PHARMA, INC
  • Patent number: 8138157
    Abstract: A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to an area such as an open wound having an orthopedic implant therein and provides a therapeutically effective level of drug to the patient over therapeutically effective period of time.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: March 20, 2012
    Assignee: Flow Pharma, Inc.
    Inventor: Reid M. Rubsamen